Login to Your Account

Actelion Shares Slide On Phase III Failure Of Veletri

By Cormac Sheridan

Wednesday, November 10, 2004
Actelion Ltd. lost almost one-quarter of its value Monday following news that it halted a Phase III trial of its drug for acute heart failure, Veletri, after an interim analysis indicated that it would fail to attain its primary endpoints. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription